List of Excipients in Branded Drug CRESTOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	CRESTOR	rosuvastatin calcium	0310-0755	CELLULOSE, MICROCRYSTALLINE
AstraZeneca Pharmaceuticals LP	CRESTOR	rosuvastatin calcium	0310-0755	FERRIC OXIDE YELLOW
AstraZeneca Pharmaceuticals LP	CRESTOR	rosuvastatin calcium	0310-0755	HYPROMELLOSE
AstraZeneca Pharmaceuticals LP	CRESTOR	rosuvastatin calcium	0310-0755	LACTOSE MONOHYDRATE
AstraZeneca Pharmaceuticals LP	CRESTOR	rosuvastatin calcium	0310-0755	TITANIUM DIOXIDE
AstraZeneca Pharmaceuticals LP	CRESTOR	rosuvastatin calcium	0310-0755	TRIACETIN

Crestor Excipient Strategy and Commercial Opportunities for Rosuvastatin Calcium

Last updated: September 9, 2026

Crestor is the branded rosuvastatin calcium tablet developed by AstraZeneca. Its commercial opportunity has shifted from originator exclusivity to generic cost leadership, differentiated oral delivery, and excipient-enabled lifecycle products. The core immediate-release formulation uses conventional, widely available excipients, which limits composition-of-matter barriers but creates opportunities in manufacturability, dose flexibility, taste masking, modified release, and patient-specific delivery.

What is Crestor and which excipients does it contain?

Crestor contains rosuvastatin calcium, a synthetic HMG-CoA reductase inhibitor. The U.S. product is an immediate-release, film-coated tablet available in 5 mg, 10 mg, 20 mg, and 40 mg strengths.[1]

The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Excipient	Primary function
Tablet core	Lactose monohydrate	Diluent and compressibility aid
Tablet core	Microcrystalline cellulose	Filler, binder, tablet-strength enhancer
Tablet core	Tribasic calcium phosphate	Diluent and mineral-based compression aid
Tablet core	Crospovidone	Superdisintegrant
Tablet core	Magnesium stearate	Lubricant
Film coating	Hypromellose	Film former
Film coating	Titanium dioxide	Opacifier and pigment
Film coating	Ferric oxide	Colorant
Film coating	Triacetin	Plasticizer

The formulation is technologically conventional. It does not depend on a proprietary lipid carrier, complexation system, nanoparticle platform, osmotic pump, or controlled-release polymer. That profile lowers manufacturing complexity for generic developers but also limits opportunities to differentiate a product through simple excipient substitution.

What role does each Crestor excipient play?

Lactose monohydrate and microcrystalline cellulose provide bulk and support tablet compression. Tribasic calcium phosphate contributes additional filler capacity and can influence powder flow, density, and tablet hardness.

Crospovidone promotes rapid tablet breakup. This is important because the product is designed for immediate release rather than sustained delivery. Magnesium stearate reduces tooling friction, although excessive lubrication can impair tablet wettability and dissolution.

Hypromellose, titanium dioxide, ferric oxide, and triacetin create the film coat. The coating identifies dose strength, protects the tablet surface, improves swallowability, and supports product appearance. Color differentiation is commercially relevant because Crestor is marketed in several strengths and the 40 mg dose carries a higher risk of medication error if tablet appearance is not clearly differentiated.

What excipient strategy is required for rosuvastatin generic tablets?

A generic rosuvastatin developer does not need to replicate every Crestor excipient. The ANDA pathway generally permits a different inactive-ingredient system if the product meets pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.[2]

The practical strategy is to preserve the performance attributes that matter for approval:

1. Immediate and reproducible disintegration.
2. Comparable dissolution across relevant pH conditions.
3. Consistent rosuvastatin content and uniformity.
4. Adequate tablet hardness and friability.
5. Chemical and physical stability.
6. Acceptable impurity control.
7. Manufacturing robustness at commercial scale.

The most defensible generic formulation will normally use established excipients with strong regulatory histories rather than novel materials. Lactose, microcrystalline cellulose, calcium phosphate, crospovidone, magnesium stearate, hypromellose, and conventional pigments are widely accepted materials. The main development risk is not excipient availability. It is achieving dissolution and bioequivalence while controlling rosuvastatin degradation, blend uniformity, compression behavior, and film-coat performance.

Which excipient substitutions offer the most commercial value?

Potential substitutions include:

• Replacing lactose with mannitol, anhydrous lactose, or dibasic calcium phosphate for improved moisture control or compression.
• Replacing crospovidone with croscarmellose sodium or sodium starch glycolate.
• Using silicified microcrystalline cellulose to improve flow and tablet strength.
• Reducing magnesium stearate sensitivity through optimized lubrication time or alternative lubricants.
• Using hypromellose-based aqueous coating systems to reduce solvent handling.
• Using iron oxide or other approved pigments to maintain strength-specific color coding.
• Introducing co-processed excipients to simplify scale-up and reduce manufacturing variability.

These changes can reduce cost or improve process capability, but they are unlikely to create durable patent protection on their own. The commercial value generally comes from lower manufacturing cost, fewer rejects, higher throughput, improved stability, or easier supply qualification.

How difficult is rosuvastatin formulation from an excipient perspective?

Rosuvastatin is more formulation-sensitive than a simple highly soluble, highly permeable small molecule. Rosuvastatin calcium has limited aqueous solubility that varies with pH, and its absorption can be affected by transport and interaction mechanisms. The product nevertheless has a well-established immediate-release profile, and the approved tablet formulation does not require an advanced delivery platform.

Key development variables include:

• Particle size and milling conditions for rosuvastatin calcium.
• Calcium salt form and polymorphic control.
• Drug loading at the 40 mg strength.
• Blend uniformity at the 5 mg strength.
• Disintegrant efficiency.
• Lubricant concentration and mixing time.
• Dissolution across acidic and near-neutral media.
• Protection against moisture and oxidative degradation.
• Compatibility between the active ingredient and alkaline or mineral fillers.

The 5 mg and 40 mg strengths create different development problems. The 5 mg tablet requires strong content-uniformity controls because the active represents a small fraction of the tablet mass. The 40 mg tablet requires adequate compression, acceptable tablet size, and reliable dissolution at a higher drug load.

What formulation patents protect Crestor?

Crestor’s strongest historical protection came from patents covering rosuvastatin and related chemical subject matter, not from a highly differentiated excipient platform. The principal U.S. patent associated with rosuvastatin was U.S. Patent No. 6,316,023, assigned to AstraZeneca, with protection extending into 2020 before applicable pediatric adjustments and litigation outcomes.[3]

AstraZeneca also pursued patents and regulatory listings involving rosuvastatin calcium, crystalline forms, intermediates, and related chemical processes. The scope and enforceability of individual patents depended on claim construction, validity challenges, terminal disclaimers, and settlement agreements.

The formulation lesson is direct: a generic company seeking to enter the rosuvastatin market has historically faced greater risk from active-ingredient, salt-form, and process claims than from the standard excipient combination used in the marketed tablet.

Are Crestor’s excipients themselves strongly protected?

The conventional excipient combination has limited standalone patent strength. Lactose, microcrystalline cellulose, crospovidone, calcium phosphate, magnesium stearate, hypromellose, titanium dioxide, ferric oxide, and triacetin are established pharmaceutical materials.

Potentially protectable subject matter would more likely involve:

• A specific dissolution-enhancing composition.
• A defined particle-size distribution.
• A novel crystalline or amorphous rosuvastatin form.
• A stability-improving excipient ratio.
• A manufacturing process that reduces impurities.
• A taste-masked pediatric or orally disintegrating dosage form.
• A fixed-dose combination with a second cardiovascular medicine.
• A controlled-release or targeted-delivery system.

A formulation patent must provide a measurable technical advantage. A substitution that merely replaces one conventional filler with another is vulnerable to obviousness and enablement challenges.

When did Crestor lose exclusivity and generic entry begin?

Crestor received U.S. Food and Drug Administration approval in August 2003.[1] Its five-year new chemical entity exclusivity expired in 2008. Patent protection delayed broad generic entry beyond the end of statutory exclusivity.

Milestone	Approximate date	Commercial effect
FDA approval of Crestor	August 2003	Originator launch
NCE exclusivity expiration	August 2008	ANDA approvals became possible, subject to patents
Principal rosuvastatin patent period	2020 era	Major patent barrier approached expiration
Generic rosuvastatin launches	2016 onward in the U.S.	Price competition accelerated
Current market structure	Post-2020	Multiple generic suppliers and limited branded leverage

AstraZeneca reached settlement arrangements with several generic applicants, permitting some earlier entry than the full patent term would otherwise have allowed. Generic rosuvastatin became commercially available in the United States before the principal patent term ended through authorized and settlement-related entry arrangements.[4]

What was the Orange Book status of Crestor?

The Orange Book historically listed Crestor as an approved rosuvastatin calcium product with patent information submitted by AstraZeneca.[5] The relevant legal issues included patent certifications under Paragraph IV of the Hatch-Waxman Act.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a Paragraph IV certification can trigger patent litigation and, when the first qualifying applicant is involved, a potential 180-day generic exclusivity period.

Crestor-related litigation involved several generic applicants, including Teva, Apotex, Cobalt, and Mylan-related entities. The disputes centered on patent validity, infringement, and the timing of generic launch. The outcome was a staggered generic-entry environment rather than an immediate full-market opening.

Which companies challenged Crestor patents?

The major generic challenges involved companies seeking approval for rosuvastatin calcium tablets. Publicly reported challengers included:

• Teva Pharmaceuticals.
• Apotex.
• Cobalt Pharmaceuticals.
• Mylan and affiliated entities.
• Actavis or Watson-related entities.

AstraZeneca used patent litigation and settlements to manage the timing of entry. The commercial result was earlier competition than an uncompromised patent term would have produced, while preserving significant branded revenue during the high-value period.

What commercial opportunities exist for Crestor excipients?

The most attractive opportunities are in generic supply, lifecycle formulations, and manufacturing services rather than direct replication of the original tablet.

Generic excipient supply

High-volume generic rosuvastatin creates recurring demand for:

• Direct-compression microcrystalline cellulose.
• Crospovidone and other superdisintegrants.
• Calcium phosphate fillers.
• Pharmaceutical-grade magnesium stearate.
• Film-coating systems.
• Iron oxide pigments.
• Low-moisture excipient grades.
• Co-processed compression aids.

Suppliers can compete through validated global supply, consistent particle-size distribution, low bioburden, strong change-control systems, and reliable regulatory documentation. For a mature generic, supply continuity can be more valuable than a small unit-price reduction.

Excipient systems for cost reduction

A developer can reduce cost by optimizing tablet weight, shortening blending time, increasing compression speed, and reducing coating-cycle duration. Co-processed excipients may permit fewer raw materials and simpler process validation.

The strongest business case exists where an excipient system improves overall cost of goods rather than merely lowering the price of one ingredient. A 1% reduction in excipient cost has limited value if it increases rejects, slows compression, or creates dissolution failures.

Orally disintegrating and pediatric products

Rosuvastatin is prescribed across a broad adult population, including older patients who may have difficulty swallowing tablets. An orally disintegrating tablet, mini-tablet, sprinkle formulation, or rapidly dispersible dosage form could create a differentiated product.

The commercial barriers include:

• Rosuvastatin’s bitter taste.
• Dose accuracy at low strengths.
• Moisture sensitivity.
• Mechanical fragility.
• Packaging requirements.
• Need to demonstrate bioequivalence or obtain approval through an appropriate regulatory pathway.

Taste masking could use polymer coatings, ion-exchange systems, lipid barriers, or multiparticulate technology. These products may support a 505(b)(2) strategy if the formulation or labeling differs materially from approved immediate-release tablets, although the regulatory pathway depends on the proposed product and supporting data.[6]

Fixed-dose cardiovascular combinations

Rosuvastatin is a logical component of fixed-dose combinations with ezetimibe, amlodipine, telmisartan, losartan, or other cardiovascular agents. The technical challenge is excipient compatibility and dissolution control across multiple active ingredients.

A fixed-dose combination can improve adherence and create a differentiated commercial product, but its patent value depends on the specific combination, formulation architecture, clinical positioning, and regulatory status. Combination products also face more complex impurity, content-uniformity, and stability programs.

What patent and regulatory barriers affect new Crestor formulations?

A new rosuvastatin formulation must be screened against several IP categories:

IP category	Typical risk
Active ingredient claims	Salt, stereochemistry, chemical structure
Solid-state claims	Polymorphs, hydrates, crystalline forms
Process patents	Synthesis, purification, particle engineering
Formulation patents	Excipient ratios, dissolution systems, stability
Method-of-use patents	Specific patient populations or dosing regimens
Combination patents	Rosuvastatin plus another cardiovascular agent
Manufacturing know-how	Scale-up parameters, coating, milling, impurity control

The principal manufacturing barrier is not the availability of ordinary excipients. It is control of the active ingredient’s solid state, particle properties, impurities, and reproducible dissolution.

FDA approval also requires compliance with current good manufacturing practice, validated analytical methods, stability testing, process controls, and bioequivalence requirements. A product that uses different excipients can still face a substantial development program if the substitutions alter dissolution or exposure.

How does Crestor compare with other statin products?

Product	Active ingredient	Formulation profile	Generic opportunity
Crestor	Rosuvastatin calcium	Immediate-release film-coated tablet	Broad generic competition; differentiated delivery remains possible
Lipitor	Atorvastatin calcium	Immediate-release tablet	Mature generic market with extensive supplier competition
Zocor	Simvastatin	Immediate-release tablet	Low-cost generic market; limited branded leverage
Pravachol	Pravastatin sodium	Immediate-release tablet	Established generic market
Lescol	Fluvastatin sodium	Immediate-release and extended-release products	Modified-release expertise is more relevant
Livalo	Pitavastatin calcium	Immediate-release tablet	Smaller market with potential formulation differentiation

Crestor had a higher-value commercial position than many older statins because of strong LDL-lowering efficacy and broad use across cardiovascular-risk populations. Once generic entry expanded, its excipient-related opportunity became a scale and differentiation question rather than a conventional branded-prescription opportunity.

What is the revenue exposure from Crestor patent expiry?

Crestor was one of AstraZeneca’s largest products before generic erosion. Reported sales were approximately $5 billion in the mid-2010s, with revenue declining as generic competition expanded.[7] The exposure included direct Crestor sales, price reductions, payer substitution, and loss of formulary preference.

For generic manufacturers, the opportunity was substantial because rosuvastatin had:

• High historical prescription volume.
• Multiple approved strengths.
• Simple oral administration.
• Strong physician familiarity.
• Broad use in primary and secondary prevention.
• A mature FDA regulatory pathway.

For excipient suppliers, the opportunity was smaller per tablet but more durable across multiple manufacturers and geographies.

What generic launch scenarios exist for rosuvastatin?

The main commercial scenarios are:

1. Low-cost conventional tablets. This is the dominant strategy and depends on reliable bioequivalence, efficient compression, and competitive API sourcing.
2. Authorized or settlement-related entry. Earlier entry can capture market share before complete patent expiry.
3. Value-added generic. A product may differentiate through smaller tablets, improved swallowability, lower pill burden, or packaging.
4. Pediatric or geriatric formulation. Orally disintegrating or mini-tablet formats can target adherence barriers.
5. Fixed-dose combination. Combining rosuvastatin with another cardiovascular active can support adherence and commercial differentiation.
6. Geographic expansion. Local regulatory requirements, reference-product status, and patent terms vary by jurisdiction.

Biosimilar risk is not relevant to Crestor because rosuvastatin is a chemically synthesized small molecule, not a biologic. The competitive risk comes from conventional generics, authorized generics, combination products, and potential 505(b)(2) formulations.

Key Takeaways

• Crestor is an immediate-release rosuvastatin calcium film-coated tablet using conventional excipients.
• The core formulation contains lactose monohydrate, microcrystalline cellulose, tribasic calcium phosphate, crospovidone, magnesium stearate, hypromellose, titanium dioxide, ferric oxide, and triacetin.
• The original commercial barrier came primarily from rosuvastatin chemical, solid-state, and related patent protection, not from an unusual excipient platform.
• Generic developers can substitute excipients if they preserve dissolution, bioequivalence, stability, and content uniformity.
• The strongest excipient opportunities are cost reduction, process robustness, orally disintegrating delivery, taste masking, pediatric or geriatric formats, and fixed-dose combinations.
• Conventional excipient patents are unlikely to provide strong exclusivity without a defined technical effect.
• The largest commercial opportunity is generic scale. The highest-margin opportunity is differentiated delivery or combination therapy.
• Biosimilar competition does not apply. Generic and formulation competition does.

FAQs

Can lactose-free rosuvastatin tablets be developed?

Yes. A developer can replace lactose with mannitol, calcium phosphate, microcrystalline cellulose, or another suitable diluent, subject to formulation performance, stability, and FDA approval requirements.

Does rosuvastatin require a lipid-based formulation?

No. Approved Crestor tablets use a conventional solid oral formulation. A lipid-based system could be investigated for a specific performance objective, but it is not required for standard immediate-release approval.

Can a new excipient create market exclusivity for rosuvastatin?

A new excipient alone rarely creates durable exclusivity. Protection is more credible when the excipient produces a demonstrated improvement in dissolution, stability, bioavailability, taste masking, or patient administration.

Is an orally disintegrating rosuvastatin product commercially attractive?

Potentially. The target populations include older adults and patients with swallowing difficulty. Commercial success would depend on taste masking, dose uniformity, packaging stability, payer positioning, and a regulatory pathway that supports meaningful differentiation.

Are Crestor formulation patents still the main generic-entry barrier?

No. The historical principal barriers were chemical, solid-state, and related rosuvastatin patents. In the current mature market, manufacturing economics, API supply, regulatory execution, and commercial contracting are more important than the original Crestor excipient combination.

References

1. U.S. Food and Drug Administration. (2023). Crestor (rosuvastatin calcium) prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,316,023: Rosuvastatin compounds. AstraZeneca AB.

4. Federal Trade Commission. (2017). Authorized generic drugs: Short-term effects and long-term impact. U.S. Federal Trade Commission.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.

7. AstraZeneca PLC. (2016). Annual report and Form 20-F 2015. London, United Kingdom: AstraZeneca.